All In Biotech

NDA 019465 · Hospira

Sodium Chloride 0.9% In Plastic Container

Sodium Chloride · Injection

Last checked: Nov 20, 2026Latest source record: May 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Jul 15, 1985

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

75,824

60,821 serious, 6,415 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 19, 2026.

INDICATIONS AND USAGE Intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient. In this dosage form, Sodium Chloride Injection, USP is intended to be used as a diluent for the contents of an ADD-Vantage vial, or single-dose vials with 20 mm closure using the ADD-Vantage ADDAPTOR™.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 15, 1985 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · SODIUM CHLORIDE 900MG/100ML · SOLUTION, INJECTION · Prescription · TE AP
  • SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · SODIUM CHLORIDE 450MG/50ML (9MG/ML) · SOLUTION, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myelosuppression5,526
  • nausea5,445
  • dyspnoea4,775
  • off label use4,708
  • headache4,416
  • pyrexia4,328
  • fatigue4,226
  • vomiting3,888
  • diarrhoea3,774
  • pneumonia3,446
  • pain2,969
  • white blood cell count decreased2,947

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004118
2005182
2006272
2007248
2008266
2009413
2010399
2011585
2012852
2013690
20141,147
20152,148
20163,096
20172,485
20183,596
20195,072
20206,387
20215,734
20227,390
20237,783
20249,511
20259,912
20267,535

Recalls

2 FDA enforcement reports for this application.

  • Apr 7, 2015 · Class II · Terminated

    Lack of Sterility Assurance: The product has the potential to leak at the administrative port.

  • May 4, 2012 · Class II · Terminated

    Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Dec 3, 2025

    Sodium Chloride 0.9%, Injection, 100 mL ADD-Vantage® Flexible Container (NDC 0409-7101-67). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Dec 3, 2025

    Sodium Chloride 0.9%, Injection, 250 mL ADD-Vantage® Flexible Container (NDC 0409-7101-02). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Dec 3, 2025

    Sodium Chloride 0.9%, Injection, 50 mL ADD-Vantage® Flexible Container (NDC 0409-7101-66). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.